浩欧博收盘下跌3.13%，滚动市盈率221.62倍，总市值76.75亿元

Company Overview - Jiangsu Haobio Pharmaceutical Co., Ltd. specializes in the research, production, and sales of in vitro diagnostic reagents, with key products including allergy and autoimmune reagents [2] - The company holds 226 product registration certificates and 57 patents, and is recognized as a high-tech enterprise with multiple awards and honors [2] Financial Performance - For Q1 2025, the company reported revenue of 77.61 million yuan, a year-on-year decrease of 9.33%, and a net profit of 1.64 million yuan, down 56.97% [2] - The gross profit margin for the same period was 57.98% [2] Market Position - As of July 30, the company's stock closed at 120.91 yuan, down 3.13%, with a rolling price-to-earnings (PE) ratio of 221.62, significantly higher than the industry average of 55.15 [1][3] - The total market capitalization of the company is 7.675 billion yuan [1] Institutional Holdings - By the end of Q1 2025, 12 institutions held shares in the company, all of which were funds, with a total holding of 1.1392 million shares valued at 15.5 million yuan [1]